U.S. Markets closed

Galapagos Soars After Rheumatoid Arthritis Drug Meets Primary Endpoint

Alexander Nicoll

rose sharply Friday after the biotechnology company announced positive results for both doses of its rheumatoid arthritis drug, filgotinib, in Phase 3 trials. , showed patients improving more than a placebo in attaining an American College of Rheumatology 20% response, according to a company press release. The ACR20 is the baseline measure to evaluate rheumatoid arthritis treatments in clinical trials so that patients express a 20% improvement in at least three of five criteria determined by the ACR, according to the organization.